Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 NF7kN|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoXLR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gV2tOTUxvNTDt[Yxidm:vYTDj[YxtKGyrbnXzMEBGTDVyPUOuNFBGNTB6IN88US=> NWriW5JkOTh5NUO1NC=>
A-549 M4LT[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M17u[GN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJGEuPTR7IHz1coch[2G{Y3nuc41iKGOnbHygcIlv\XNuIFXEOVA:OS5{MFWtNFYh|ryP MkLmNVg4PTN3MB?=
MCF-7 NH3EfYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml35R5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= MnToNVg4PTN3MB?=
HT-29 NGi2S5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDIWE0zQSClb3zvckBi\GWwb3PhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUGuNlBGNTB4IN88US=> MmLnNVg4PTN3MB?=
MLM melanoma cell M3zqV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoK2R5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWxOKG2nbHHuc41iKGOnbHygcIlv\XNuIFXEOVA:OS52MFWtNFYh|ryP NFXSN20yQDd3M{Ww
M14 NYXSZWp6S3m2b4TvfIlkcXS7IHHzd4F6 MmOwTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJdieyC2ZYP0[YQh[WejaX7zeEBpfW2jbjDt[Yxidm:vYTDjZY5k\XJiKF2xOEkh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> M{mxXVEzPzJ7NkSw
SK-OV3 NFvHOHdEgXSxdH;4bYNqfHliYYPzZZk> M4SzOWlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB1\XO2ZXSgZYdicW6|dDDoeY1idiCxdnHybYFvKGOjbnPldkApW0tvT2[zLUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> M3vWfFEzPzJ7NkSw
HL60 cells MmfQR5l1d3SxeHnjbZR6KGG|c3H5 M3XzNVczKGh? NHLL[GdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODBzIN88US=> M2CySFIxPzNzM{W1
SK-OV-3 MnLoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVW0PEBp MlfyS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suV1ZvMzDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwNVMh|ryP MnLTNVg4OjJzMke=
HepG2 cells M{H6U2N6fG:2b4jpZ4l1gSCjc4PhfS=> NH6yVGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyxiSVO1NF0xNjByMEG0JO69VQ>? MVmxO|EzPzB4MR?=
ZR-75-1 M3\4eWN6fG:2b4jpZ4l1gSCjc4PhfS=> M{noU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFqULUe1MVEh[2WubDDsbY5mNCCLQ{WwQVAvODByMkSg{txO M3jCOFE4OjR7NkS5
HeLa cell NVPiTXBRS3m2b4TvfIlkcXS7IHHzd4F6 M3Gwd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEinTHGgZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOyEQvF2= MnX3NVczPDl4NEm=
HCT116 cell MVHDfZRwfG:6aXPpeJkh[XO|YYm= NWPtV|AzS3m2b4TvfIlkcXS7IHHnZYlve3RiSFPUNVE3KGOnbHygcIlv\SxiSVO1NF0xNjByMEO1JO69VQ>? NWCwfpUyOTd{NEm2OFk>
KBV1 cells M{\ST2N6fG:2b4jpZ4l1gSCjc4PhfS=> NFzqSIY4OiCq MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjD2bY5jdGG|dHnu[U1z\XOrc4ThcpQhU0KYMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByNDFOwG0> NG\CSpgzODd|MUO1OS=>
SKOV3 NYrRO3BpS3m2b4TvfIlkcXS7IHHzd4F6 MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? NX\JcnRYOjRyMU[wNFI>
SKOV3 cells MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYjZN5VCT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMESyJO69VQ>? NEnjblMzOzd5MkOwPS=>
HeLa cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= MnLGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC1NUDPxE1? NIrWR4YyQTh5OUe1PC=>
DU145 cells MmG2R5l1d3SxeHnjbZR6KGG|c3H5 M{jlUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNFU1KM7:TR?= NVy1N|d6OjRyMU[wNFI>
DU145 cells MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFHoT|FIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODByNUSg{txO MknGNlM4PzJ|MEm=
SK-N-BE NEfCV5NRem:uaX\ldoF1cW:wIHHzd4F6 M1vJbVczKGh? M2POTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU5vQlWgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMEW4JO69VQ>? MVyyNlMzQTV4MR?=
NCIH460 cells NF73XoxEgXSxdH;4bYNqfHliYYPzZZk> MVO0PEBp MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2lJPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB4IN88US=> NWHyN4c{OTh|MEO4OFk>
KB-VIN10 cells NH3HUnRRem:uaX\ldoF1cW:wIHHzd4F6 NUPD[|gzPzJiaB?= NGeySGFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP M2TnNFIyPjRzN{Cw
HCT116 cells MlO2R5l1d3SxeHnjbZR6KGG|c3H5 NEfrdoI4OiCq MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? MknRNlE6PTV2NUS=
DU145 cells MYLDfZRwfG:6aXPpeJkh[XO|YYm= NV64V5lHPDhiaB?= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxQCEQvF2= MYGxPFMxOzh2OR?=
RS4:11 cells NYXPeJo{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MVW3NkBp MmDXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUU{S6NVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IDizMUg1NDVvZHnt[ZRpgWy2aHnhfo9tNTJveXypMVItPS2maYDo[Y56dHSndILhfo9tcXWvIHLyc41q\GVidHXzeEwhUUN3ME2wMlAxODhizszN NGjwNJgzPTd6NU[wOS=>
HCT 116 NGPZPJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEfkcnNEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCqdX3hckBkd2yxbjD0eY1weiCKQ2SgNVE3NCCLQ{WwQVAvODByOTFOwG0> M{\ycFEyPzF2NkGz
HeLa cells M12zd2N6fG:2b4jpZ4l1gSCjc4PhfS=> MVq3NkBp M2e5bWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTB;MD6wNFA6KM7:TR?= NXrOU2FHOjR4Nkm4PFg>
BNL 1ME A.7R.1 cells NUnJ[Zk1S3m2b4TvfIlkcXS7IHHzd4F6 NH3B[ldEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDVkxiMV3FJGEvP1JwMTDj[YxteyxiSVO1NF0xNjByMEmg{txO M37weVI2Pzh3NkC1
Calu6 NFvDdXRRem:uaX\ldoF1cW:wIHHzd4F6 Mln1OFghcA>? NFnlS3RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPhcJU3KGGodHXyJFQ5KGi{czDifUB{eGWldILvdIhwfG:vZYTyfUwhUUN3ME2wMlAxODl2IN88US=> M1fOZVIyPzd2NEm5
melanoma B16 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHL2OHBEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? M1TCVVEyPzF2NkGz
DU145 cells MnPvR5l1d3SxeHnjbZR6KGG|c3H5 M3zmO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M4noTlIxPDl4OUKz
HCT116 cells M1vvUHBzd2yrZnXyZZRqd25iYYPzZZk> M1\WOFczKGh? MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NHvy[48zOTFzMkGzNC=>
HCT15 cells NW\SeJg4WHKxbHnm[ZJifGmxbjDhd5NigQ>? MnXaO|IhcA>? MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEG1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGg{txO MUOyNVEyOjF|MB?=
HL60 cells NX;ZWGlCWHKxbHnm[ZJifGmxbjDhd5NigQ>? MY[3NkBp MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NWHheFB{OjF4NkOzNVk>
A10 cells MnjqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXy0PEBp MmHES5Jwf3SqIHnubIljcXSrb36gc4YhemG2IFGxNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NVOwZoVzOjJyNESxOlQ>
HUVEC cells MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NI[2TJo1QCCq M3mwb2dzd3e2aDDpcohq[mm2aX;uJI9nKEiXVlXDJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MXuyNlA1PDF4NB?=
HL60 cells NH:3XW1EgXSxdH;4bYNqfHliYYPzZZk> NUTReIY3PzJiaB?= M1G0OWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NFrpRVQzOjF|NkOxNi=>
HL60 cells Mo\ZVJJwdGmoZYLheIlwdiCjc4PhfS=> NEjObYU4OiCq MmfMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MnuxNlI2PzhzMUG=
NCI-H522 cells M1;Xe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIXB[Wg1QCCq M{HFRmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO NXPifHY5OjJ7OEKxNlI>
MDA-MB-435 cells M4XqSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF[xcIE1QCCq NFPQV|RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP M4PHO|IzQTh{MUKy
OVCAR3 NVTrSIpkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXO0PEBp NWG0OWJCT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKzJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO NHmxbpAzOjl6MkGyNi=>
NCI/ADR-RES cells NW\vRlExT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2nDc|Q5KGh? M1;2b2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NInWbpEzOjl6MkGyNi=>
PC3 cells M1\ZTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVvYeZJMPDhiaB?= MlH6S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP M1W2O|IzQTh{MUKy
DU145 cells M3n6SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkfZOFghcA>? MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= M12xNlIzQTh{MUKy
MDA-MB-231 cells M{XHNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVO0PEBp MmDMS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MVuyNlk5OjF{Mh?=
CEM cells M{DsWWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4XDS|czKGh? NWHXVI9MS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NHraPVUzOjZ5NkK0Oy=>
HCT116 cells M1HqWWN6fG:2b4jpZ4l1gSCjc4PhfS=> MUe3NkBp NE\H[ItEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> MlXONlI3PzZ{NEe=
MDA-MB-435 cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= NFHIVIs4OiCq M1vae2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MnvoNlI3PzZ{NEe=
HaCaT cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 NH30VlVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjhR4FVKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> MmDCNlMxPjN2MEG=
HL60 cells NF\3SItRem:uaX\ldoF1cW:wIHHzd4F6 NX7kbpY5PzJiaB?= NGrSUplCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MVyyN|EyPzF5MR?=
HL60 cells MlPYVJJwdGmoZYLheIlwdiCjc4PhfS=> MWe3NkBp M3\oVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliKEOtLFQtPS2maX3leIh6dHSqaXH6c4wuOi27bDmtNkw2NWSrcHjlcpltfGW2cnH6c4xqfW1iYoLvcYll\SC2ZYP0MEBKSzVyPUCuNFAyKM7:TR?= M3TTO|I2Pzh3NkC1
HT-29 NYjq[WxDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIrzd5dIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M1HlT|I2Pjh7MUGx
HL60 cells M{XORXBzd2yrZnXyZZRqd25iYYPzZZk> MYi3NkBp NUnPXohrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MWCyNFQzODR|OR?=
Hs578T cells M1vkXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX\G[JI{PDhiaB?= M3;Ob2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGh{PTd6VDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> M{\2eVIzQTh{MUKy
HL60 cells NGLRXG9EgXSxdH;4bYNqfHliYYPzZZk> MVu3NkBp NUDSTnI3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NH;JUmEzOzR2NUS5Oi=>
SKOV3 cells MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2nMOWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMV1Z|IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MoDDNlU3QDlzMUG=
MDA-MB-468 cells NF\sXJdEgXSxdH;4bYNqfHliYYPzZZk> MYW0JIRigXN? MnvIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxNUDPxE1? Mo\5NlQzOTB3MEO=
MCF7 cells NUDEeGtMWHKxbHnm[ZJifGmxbjDhd5NigQ>? MX23NkBp NVW4XYIzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzMUGg{txO NVfMb5BDOjJ|Mkm1OlE>
H460 NUX1fldYS3m2b4TvfIlkcXS7IHHzd4F6 MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVIh|ryP MlTpNVg4QDN{MEe=
H460 M4\qbXBzd2yrZnXyZZRqd25iYYPzZZk> M3HRXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczygTWM2OD1yLkCwNVI1KM7:TR?= MUWxOlczOjZ|Mx?=
NCI-H460 cells M2LPdmN6fG:2b4jpZ4l1gSCjc4PhfS=> Mnz2O|IhcA>? NFv4dopEgXSxdH;4bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkB1\XO2LDDJR|UxRTBwMECxN{DPxE1? MnLFNVg{QTZ6NUe=
OVCAR8 cells MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\yPVYhcA>? MorxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ6IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHAu\2y7Y3;wdo91\WmwIHHmeIVzKDl4IHjyd{whUUN3ME2wMlAxOTNizszN MXeyNlA1PDF4NB?=
NCI/ADR-RES cells MkLKR5l1d3SxeHnjbZR6KGG|c3H5 M1z0S2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD1yLkCwNVMh|ryP NUPpd4tROjN{MUS0OVI>
OVCAR8 cells NWSxW49wS3m2b4TvfIlkcXS7IHHzd4F6 MXO5OkBp M1L2dWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB7NjDodpMh[nliR3nlcZNiKHO2YXnubY5oNWKjc3XkJIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTB;MD6wNFE{KM7:TR?= NI\ndY8zPTB{NUm5NS=>
NCI/ADR-RES cells MlnLR5l1d3SxeHnjbZR6KGG|c3H5 MkjYPVYhcA>? MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC5OkBpenNiYomgS4lmdXOjIIP0ZYlvcW6pLXLhd4VlKGyrZ3j0JI1q[3Kxc3PvdJktKEmFNUC9NE4xODF|IN88US=> NHfqUXUzPTB{NUm5NS=>
OVCAR8 cells MX\DfZRwfG:6aXPpeJkh[XO|YYm= NIHuUFhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCLQ{WwQVAvODBzMzFOwG0> NXzRPIJZOjN{MUS0OVI>
HuTu 80 cells NYHuSmNPWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1exbVczKGh? Mn;MRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gTJVVfSB6MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzM{eg{txO NITHTJMzOjN{OUW2NS=>
K562 cells NYHmV|VJS3m2b4TvfIlkcXS7IHHzd4F6 MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUCuNFAyPCEQvF2= MVixPVg{PzV7NB?=
NCI/ADR (MDR) cells NFvzXnJHfW6ldHnvckBie3OjeR?= MknRR4VtdCCleXPs[UBienKnc4SgbY4hVkOLL1HEVkApVUSUKTDj[YxteyCkeTDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTygTWM2OD1yLkCwNVUh|ryP MnraNVY{PzdzOEe=
HUVEC NUnUPFNxWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVfHT3hPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyxiSVO1NF0xNjByMUWg{txO M2\qSVE3PzJ{NkOz
KB cell MorwVJJwdGmoZYLheIlwdiCjc4PhfS=> MoXxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQjDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= MojrNVcxOzRzNEe=
KB-VIN10 cell Mm\2VJJwdGmoZYLheIlwdiCjc4PhfS=> NHm1VYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIwhdGmwZTDifUBu\XSqeXzlcoUh[my3ZTDkfYUh[XO|YYmsJGlEPTB;MD6wNFE2KM7:TR?= MVixO|A{PDF2Nx?=
Human SH-SY5Y neuroblastoma cells Mnu5SpVv[3Srb36gZZN{[Xl? NXXabJo5UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? M1fWRVE2QTZ|N{Ky
SW620 cells NInBdYFRem:uaX\ldoF1cW:wIHHzd4F6 M3XMd|czKGh? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN NUj0NWlHOjJ|Mkm1OlE>
Molt4/C8 cells NYTDbW1KWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4LTPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMtKEmFNUC9NE4xODF4IN88US=> M2HhdlE4ODN2MUWw
ACHN cell M3jN[HBzd2yrZnXyZZRqd25iYYPzZZk> Mmm1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHKnc3nzeIFvfCCDQ1jOJINmdGxibHnu[UBmgHC{ZYPzbY5oKE2GUkGgZpkhSWyjbXHyJGJtfWViYYPzZZktKEmFNUC9NE4xODF4IN88US=> MlnhNVczQDZ|OUO=
Molt4/C8 cells NF;icJNRem:uaX\ldoF1cW:wIHHzd4F6 NYjnXHI2OyCmYYnz MXrBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBOd2y2ND;DPEBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUC9NE4xODF4IN88US=> NH\LTnoyPzRzOU[wOy=>

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
+ Expand

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395434 Completed Tumors Mateon Therapeutics September 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID